Announced Sat, 18 Jul · 13:20 IST
Rights Issue of up to Rs 50 Cr approved; two Independent Directors resign
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-9.9%1-day move
₹36.50
prior close
—
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————-9.9-14.4-18.7-22.7-26.6—————
Up moveDown movePending
AI summary
Bacil Pharma board approved a Rights Issue of up to Rs 50 Crores and an increase in authorised share capital to Rs 65 Crores, subject to shareholder approval. Two Independent Directors, Mr. Dinesh Chander Notiyal and Ms. Avani Savjibhai Godhaniya, resigned effective 9 July 2026 citing time constraints and other engagements. Purva Sharegistry, Axis Bank, and Acuite Ratings were appointed as registrar, banker, and monitoring agency for the issue.
Likely market impact
Rights issue may dilute existing shareholders. Simultaneous exit of two independent directors may raise concerns on board independence and composition.